Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fenobam - Autism Therapeutics

Drug Profile

Fenobam - Autism Therapeutics

Alternative Names: AT002; Fenobam hydrochloride; NPL-2009

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FRAXA Research Foundation; Neuropharm
  • Class Chlorobenzenes; Imidazoles; Small molecules; Urea compounds
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • No development reported Fragile X syndrome

Most Recent Events

  • 30 Sep 2015 No recent reports of development identified - Phase-I/II for Fragile X syndrome in USA (PO)
  • 21 Dec 2011 Autism Therapeutics acquires Neuropharm
  • 07 Jan 2009 Pharmacokinetics, safety and efficacy data from a phase I/II trial in Fragile X Syndrome released by Neuropharma ,
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top